Cargando…
Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1
Vasohibin-1 (VASH1) is a unique endogenous inhibitor of angiogenesis that is induced in endothelial cells by pro-angiogenic factors. We previously reported renoprotective effect of adenoviral delivery of VASH1 in diabetic nephropathy model, and herein investigated the potential protective role of en...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178006/ https://www.ncbi.nlm.nih.gov/pubmed/25255225 http://dx.doi.org/10.1371/journal.pone.0107934 |
_version_ | 1782336876541116416 |
---|---|
author | Hinamoto, Norikazu Maeshima, Yohei Yamasaki, Hiroko Nasu, Tatsuyo Saito, Daisuke Watatani, Hiroyuki Ujike, Haruyo Tanabe, Katsuyuki Masuda, Kana Arata, Yuka Sugiyama, Hitoshi Sato, Yasufumi Makino, Hirofumi |
author_facet | Hinamoto, Norikazu Maeshima, Yohei Yamasaki, Hiroko Nasu, Tatsuyo Saito, Daisuke Watatani, Hiroyuki Ujike, Haruyo Tanabe, Katsuyuki Masuda, Kana Arata, Yuka Sugiyama, Hitoshi Sato, Yasufumi Makino, Hirofumi |
author_sort | Hinamoto, Norikazu |
collection | PubMed |
description | Vasohibin-1 (VASH1) is a unique endogenous inhibitor of angiogenesis that is induced in endothelial cells by pro-angiogenic factors. We previously reported renoprotective effect of adenoviral delivery of VASH1 in diabetic nephropathy model, and herein investigated the potential protective role of endogenous VASH1 by using VASH1-deficient mice. Streptozotocin-induced type 1 diabetic VASH1 heterozygous knockout mice (VASH1(+/−)) or wild-type diabetic mice were sacrificed 16 weeks after inducing diabetes. In the diabetic VASH1(+/−) mice, albuminuria were significantly exacerbated compared with the diabetic wild-type littermates, in association with the dysregulated distribution of glomerular slit diaphragm related proteins, nephrin and ZO-1, glomerular basement membrane thickning and reduction of slit diaphragm density. Glomerular monocyte/macrophage infiltration and glomerular nuclear translocation of phosphorylated NF-κB p65 were significantly exacerbated in the diabetic VASH1(+/−) mice compared with the diabetic wild-type littermates, accompanied by the augmentation of VEGF-A, M1 macrophage-derived MCP-1 and phosphorylation of IκBα, and the decrease of angiopoietin-1/2 ratio and M2 macrophage-derived Arginase-1. The glomerular CD31(+) endothelial area was also increased in the diabetic VASH1(+/−) mice compared with the diabetic-wild type littermates. Furthermore, the renal and glomerular hypertrophy, glomerular accumulation of mesangial matrix and type IV collagen and activation of renal TGF-β(1)/Smad3 signaling, a key mediator of renal fibrosis, were exacerbated in the diabetic VASH1(+/−) mice compared with the diabetic wild-type littermates. In conditionally immortalized mouse podocytes cultured under high glucose condition, transfection of VASH1 small interfering RNA (siRNA) resulted in the reduction of nephrin, angiopoietin-1 and ZO-1, and the augmentation of VEGF-A compared with control siRNA. These results suggest that endogenous VASH1 may regulate the development of diabetic renal alterations, partly via direct effects on podocytes, and thus, a strategy to recover VASH1 might potentially lead to the development of a novel therapeutic approach for diabetic nephropathy. |
format | Online Article Text |
id | pubmed-4178006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41780062014-10-02 Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1 Hinamoto, Norikazu Maeshima, Yohei Yamasaki, Hiroko Nasu, Tatsuyo Saito, Daisuke Watatani, Hiroyuki Ujike, Haruyo Tanabe, Katsuyuki Masuda, Kana Arata, Yuka Sugiyama, Hitoshi Sato, Yasufumi Makino, Hirofumi PLoS One Research Article Vasohibin-1 (VASH1) is a unique endogenous inhibitor of angiogenesis that is induced in endothelial cells by pro-angiogenic factors. We previously reported renoprotective effect of adenoviral delivery of VASH1 in diabetic nephropathy model, and herein investigated the potential protective role of endogenous VASH1 by using VASH1-deficient mice. Streptozotocin-induced type 1 diabetic VASH1 heterozygous knockout mice (VASH1(+/−)) or wild-type diabetic mice were sacrificed 16 weeks after inducing diabetes. In the diabetic VASH1(+/−) mice, albuminuria were significantly exacerbated compared with the diabetic wild-type littermates, in association with the dysregulated distribution of glomerular slit diaphragm related proteins, nephrin and ZO-1, glomerular basement membrane thickning and reduction of slit diaphragm density. Glomerular monocyte/macrophage infiltration and glomerular nuclear translocation of phosphorylated NF-κB p65 were significantly exacerbated in the diabetic VASH1(+/−) mice compared with the diabetic wild-type littermates, accompanied by the augmentation of VEGF-A, M1 macrophage-derived MCP-1 and phosphorylation of IκBα, and the decrease of angiopoietin-1/2 ratio and M2 macrophage-derived Arginase-1. The glomerular CD31(+) endothelial area was also increased in the diabetic VASH1(+/−) mice compared with the diabetic-wild type littermates. Furthermore, the renal and glomerular hypertrophy, glomerular accumulation of mesangial matrix and type IV collagen and activation of renal TGF-β(1)/Smad3 signaling, a key mediator of renal fibrosis, were exacerbated in the diabetic VASH1(+/−) mice compared with the diabetic wild-type littermates. In conditionally immortalized mouse podocytes cultured under high glucose condition, transfection of VASH1 small interfering RNA (siRNA) resulted in the reduction of nephrin, angiopoietin-1 and ZO-1, and the augmentation of VEGF-A compared with control siRNA. These results suggest that endogenous VASH1 may regulate the development of diabetic renal alterations, partly via direct effects on podocytes, and thus, a strategy to recover VASH1 might potentially lead to the development of a novel therapeutic approach for diabetic nephropathy. Public Library of Science 2014-09-25 /pmc/articles/PMC4178006/ /pubmed/25255225 http://dx.doi.org/10.1371/journal.pone.0107934 Text en © 2014 Hinamoto et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Hinamoto, Norikazu Maeshima, Yohei Yamasaki, Hiroko Nasu, Tatsuyo Saito, Daisuke Watatani, Hiroyuki Ujike, Haruyo Tanabe, Katsuyuki Masuda, Kana Arata, Yuka Sugiyama, Hitoshi Sato, Yasufumi Makino, Hirofumi Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1 |
title | Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1 |
title_full | Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1 |
title_fullStr | Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1 |
title_full_unstemmed | Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1 |
title_short | Exacerbation of Diabetic Renal Alterations in Mice Lacking Vasohibin-1 |
title_sort | exacerbation of diabetic renal alterations in mice lacking vasohibin-1 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178006/ https://www.ncbi.nlm.nih.gov/pubmed/25255225 http://dx.doi.org/10.1371/journal.pone.0107934 |
work_keys_str_mv | AT hinamotonorikazu exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT maeshimayohei exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT yamasakihiroko exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT nasutatsuyo exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT saitodaisuke exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT watatanihiroyuki exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT ujikeharuyo exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT tanabekatsuyuki exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT masudakana exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT aratayuka exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT sugiyamahitoshi exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT satoyasufumi exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 AT makinohirofumi exacerbationofdiabeticrenalalterationsinmicelackingvasohibin1 |